Myriad Genetics, Inc [MYGN] stock prices are up 0.34% to $14.83 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MYGN shares have gain 9.85% over the last week, with a monthly amount drifted -0.34%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Myriad Genetics, Inc [NASDAQ: MYGN] stock has seen the most recent analyst activity on December 10, 2024, when UBS initiated its Neutral rating and assigned the stock a price target of $18. Previously, Leerink Partners downgraded its rating to Market Perform on December 09, 2024, and dropped its price target to $21. On September 19, 2024, Morgan Stanley initiated with a Equal-Weight rating and assigned a price target of $32 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $35 on August 28, 2024. Scotiabank initiated its recommendation with a Sector Outperform and recommended $29 as its price target on June 27, 2024. In a note dated May 08, 2024, Leerink Partners upgraded an Outperform rating on this stock and boosted its target price from $25 to $35.
The stock price of Myriad Genetics, Inc [MYGN] has been fluctuating between $12.87 and $29.30 over the past year. Currently, Wall Street analysts expect the stock to reach $30.2 within the next 12 months. Myriad Genetics, Inc [NASDAQ: MYGN] shares were valued at $14.83 at the most recent close of the market. An investor can expect a potential return of 103.64% based on the average MYGN price forecast.
Analyzing the MYGN fundamentals
The Myriad Genetics, Inc [NASDAQ:MYGN] reported sales of 823.60M for trailing twelve months, representing a surge of 11.15%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.14%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.15 and Total Capital is -0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.29 points at the first support level, and at 13.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.23, and for the 2nd resistance point, it is at 15.62.
Ratios To Look Out For
It’s worth pointing out that Myriad Genetics, Inc [NASDAQ:MYGN]’s Current Ratio is 1.90. Further, the Quick Ratio stands at 1.73, while the Cash Ratio is 0.65. Considering the valuation of this stock, the price to sales ratio is 1.64, the price to book ratio is 1.84.
Transactions by insiders
Recent insider trading involved DIAZ PAUL J, President and CEO, that happened on Oct 11 ’24 when 15000.0 shares were sold. Officer, DIAZ PAUL J completed a deal on Oct 11 ’24 to buy 15000.0 shares. Meanwhile, Officer Ancona Margaret bought 11538.0 shares on Aug 21 ’24.
